Cellexus, the cell company that develops single-use bioreactors and cell-based technologies for biopharmaceutical research and production, has acquired the assets of Cellexus Biosystems.
Cellexus has improved the Cellmaker bioreactor systems since acquiring Biosystems' assets and will soon launch another range of products.
These include the Cellmaker Regular for the culture of E.Coli and Pichia cells and the Cellmaker Plus for the culture of all cells, including mammalian and insect.
These systems will achieve higher yields of soluble protein using the single-use Cellexusbag.
The company is also developing a range of peripheral products, including those for sampling and oxygen generation, which will further facilitate system use and performance in an even broader range of conditions.
